AEF 0117

Drug Profile

AEF 0117

Alternative Names: AEF0117

Latest Information Update: 06 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aelis Farma
  • Developer Aelis Farma; National Institute on Drug Abuse
  • Class Drug withdrawal therapies
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Drug abuse

Most Recent Events

  • 01 May 2018 Aelis Farma in collaboration with National Institute on Drug Abuse completes a phase I trial in Healthy volunteers in USA (NCT03443895)
  • 26 Feb 2018 Aelis Farma and National Institute on Drug Abuse completes phase I trial in Healthy volunteers in USA (NCT03325595)
  • 06 Apr 2017 Phase-I clinical trials in Drug abuse (In volunteers) in USA (PO) (NCT03325595)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top